



an Open Access Journal by MDPI

## Omics in Ovarian Cancer

Guest Editors:

**Dr. Stefania Rizzo**

1. Clinica di Radiologia Ente  
Ospedaliero Cantonale (EOC),  
Istituto Imaging della Svizzera  
Italiana, Via Tesserete 46, 6900  
Lugano, Switzerland

2. Facoltà di Scienze biomediche,  
Università della Svizzera italiana  
(USI), Via G. Buffi 13, 6900  
Lugano, Switzerland

**Dr. Lucia Manganaro**

Department of Radiological,  
Oncological, and Pathological  
Sciences, Sapienza, University of  
Rome, 00161 Rome, Italy

Deadline for manuscript  
submissions:

**closed (15 September 2022)**

### Message from the Guest Editors

Dear Colleagues,

Omics studies including, but not limited to, proteomics, radiomics, genomics, radiogenomics, transcriptomics, and metabolomics rely on the high-throughput identification and quantification of molecules or imaging biomarkers, as an expression of complex biological mechanisms. Integrative omics in ovarian cancer may represent opportunities for identifying driver genes, as well as molecular signatures, to be used for prognostication and for guiding the path to targeted therapies.

This Special Issue will cover the current state-of-the-art of different omics studies in ovarian cancer and will highlight their role for a better understanding of this pathology covering a range of topics from basic to preclinical and clinical aspects.

PD Dr. Med. Stefania Rizzo  
Dr. Med. Lucia Manganaro  
Guest Editors





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)